AU6260399A - Membrane-associated organizational proteins - Google Patents

Membrane-associated organizational proteins

Info

Publication number
AU6260399A
AU6260399A AU62603/99A AU6260399A AU6260399A AU 6260399 A AU6260399 A AU 6260399A AU 62603/99 A AU62603/99 A AU 62603/99A AU 6260399 A AU6260399 A AU 6260399A AU 6260399 A AU6260399 A AU 6260399A
Authority
AU
Australia
Prior art keywords
proteins
membrane
associated organizational
organizational
organizational proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU62603/99A
Other languages
English (en)
Inventor
Mariah R. Baughn
Neil C. Corley
Karl J Guegler
Preeti Lal
Aina D. Lu
Y. Tom Tang
Henry Yue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Pharmaceuticals Inc filed Critical Incyte Pharmaceuticals Inc
Publication of AU6260399A publication Critical patent/AU6260399A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU62603/99A 1998-09-25 1999-09-23 Membrane-associated organizational proteins Abandoned AU6260399A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15521598P 1998-09-25 1998-09-25
US60155215 1998-09-25
US15525198P 1998-10-13 1998-10-13
US60155251 1998-10-13
US17222899P 1999-05-04 1999-05-04
US60172228 1999-05-04
PCT/US1999/022082 WO2000018915A2 (fr) 1998-09-25 1999-09-23 Proteines organisationnelles associees aux membranes

Publications (1)

Publication Number Publication Date
AU6260399A true AU6260399A (en) 2000-04-17

Family

ID=27387692

Family Applications (1)

Application Number Title Priority Date Filing Date
AU62603/99A Abandoned AU6260399A (en) 1998-09-25 1999-09-23 Membrane-associated organizational proteins

Country Status (5)

Country Link
EP (1) EP1115860A2 (fr)
JP (1) JP2002525113A (fr)
AU (1) AU6260399A (fr)
CA (1) CA2343696A1 (fr)
WO (1) WO2000018915A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066740A2 (fr) * 2000-03-03 2001-09-13 Genentech, Inc. Compositions et methodes de traitement de maladies d'origine immune
US6573068B1 (en) 1997-11-13 2003-06-03 Genset, S. A. Claudin-50 protein
EP1311674A2 (fr) * 2000-08-24 2003-05-21 Genentech, Inc. Compositions et procedes de diagnostic et traitement de tumeurs
KR101294725B1 (ko) 2010-12-30 2013-08-08 연세대학교 산학협력단 인산화된 ｇｒａｓｐ를 포함하는 낭포성섬유증 치료용 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2287591A1 (fr) * 1997-03-14 1998-09-17 The Johns Hopkins University School Of Medicine Compositions proteiques a activation synaptique et methode afferente

Also Published As

Publication number Publication date
WO2000018915A2 (fr) 2000-04-06
JP2002525113A (ja) 2002-08-13
WO2000018915A3 (fr) 2000-07-27
CA2343696A1 (fr) 2000-04-06
EP1115860A2 (fr) 2001-07-18

Similar Documents

Publication Publication Date Title
AU2434199A (en) Protein
AU3562299A (en) Inhibin-hbc fusion protein
AU5844998A (en) Microemulsion
AU1550300A (en) Antigen-binding proteins
AU4922497A (en) Interleukin-18-receptor proteins
AU4281999A (en) Peptide
AU9798398A (en) Gfp-annexin fusion proteins
AU4930399A (en) Novel Polypeptide
AU1744900A (en) Gtpase associated proteins
AU6000698A (en) Proteins
AU6260399A (en) Membrane-associated organizational proteins
AU4857999A (en) Neurotransmission associated proteins
GB9816337D0 (en) Proteins
AU1458600A (en) Transmembrane 4 proteins
AU1184800A (en) Novel polypeptide
AU1552800A (en) Coupled peptides
AU4438599A (en) Human arf-related proteins
AUPP460498A0 (en) Modified proteins
AU5211899A (en) Chromatin associated proteins
AU7269298A (en) New ras-like protein
AU5446599A (en) Peptide compounds
AU3097299A (en) Nek1-related protein kinase
AU2658099A (en) Caf1-related protein
AUPP704598A0 (en) Novel polypeptide
AU3528599A (en) Prax-1 polypeptide

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase